Protalix BioTherapeutics Inc Dossier - Source-backed chat

Protalix BioTherapeutics Inc

PLXNYSE

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.34

Intrinsic Value $2.37median of 3 methodsbased on filings through 30 Jun 2026

Market Price $2.68Price as of 1 Oct 2026

Near fair valueIntrinsic value is 12% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $215.9M

Enterprise Value $188.5M

Shares Outstanding 83.7M diluted

Moat Rating Wide

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Protalix BioTherapeutics is transitioning from a clinical-stage R&D biotech into a profitable commercial-stage entity. The company's proprietary plant cell-based protein expression system, ProCellEx, has successfully delivered two approved products: Elelyso (partnered with Pfizer) and Elfabrio (partnered with Chiesi). The recent European Commission approval of Elfabrio's 2 mg/kg every-4-weeks (E4W) dosing regimen triggered a $25 million milestone payment from Chiesi, driving Q1 2026 profitability and validating the commercial viability of its pipeline. With a robust cash position of $51.1 million, no debt, and a clear path to achieving its FY 2026 revenue guidance of $78.0 to $83.0 million, Protalix is well-positioned to fund its high-value Phase 2 RELEASE trial for PRX-115 in uncontrolled gout without near-term dilutive financing.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets2 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$11.00

High · most bullish analyst$12.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.5015%

Commercial adoption of Elfabrio is slower than expected due to intense competition from established therapies (Replagal, Fabrazyme, and Galafold). Geopolitical tensions in Israel disrupt manufacturing operations at the Carmiel facility, leading to supply chain bottlenecks. PRX-115 clinical development experiences delays or safety signals in the Phase 2 trial, forcing the company to seek dilutive capital to sustain operations.

Base CaseCentral scenario

$6.0060%

Elfabrio steadily gains market share in the EU and US, achieving the targeted 15% to 20% long-term penetration. The company meets its FY 2026 revenue guidance of $78.0 to $83.0 million, supported by the $25 million Chiesi milestone and stable Elelyso sales. The PRX-115 Phase 2 trial progresses on schedule with top-line results in H2 2027. Cash reserves remain sufficient to fund operations through the clinical readouts.

Bull CaseUpside scenario

$12.0025%

Rapid commercial uptake of Elfabrio's E4W dosing regimen in the EU and US drives peak sales beyond expectations, capturing over 20% of the Fabry disease market. Concurrently, PRX-115 Phase 2 RELEASE trial results in H2 2027 demonstrate best-in-class efficacy and safety, paving the way for a lucrative global licensing partnership. Strong organic cash flows from Elelyso and Elfabrio eliminate any future dilution risk, driving significant valuation expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Validated ProCellEx platform with two FDA/EMA-approved commercial products.
Strong financial position with $51.1 million in cash, no debt, and positive net income of $18.3 million in Q1 2026.
Differentiated E4W dosing regimen for Elfabrio reduces treatment burden and enhances patient quality of life.
High-value pipeline candidate PRX-115 targeting uncontrolled gout, a large and growing market with significant unmet needs.

Key Investment Risks

High concentration risk with reliance on commercial partners Chiesi and Pfizer for marketing and distribution.
Intense competition in the Fabry and Gaucher disease markets from larger pharmaceutical companies.
Geopolitical and operational risks associated with primary manufacturing facilities located in Israel.
Clinical development risk for pipeline candidates PRX-115 and PRX-119.

Thesis Invalidation Triggers

Failure of Chiesi to effectively commercialize Elfabrio, resulting in flat or declining product sales.
Severe geopolitical escalation causing prolonged shutdown of the Carmiel manufacturing facility.
Negative or inconclusive top-line data from the PRX-115 Phase 2 RELEASE trial in H2 2027.
Unexpected regulatory or safety issues arising with Elfabrio or Elelyso.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.